LONDON (Alliance News) - Irish drugmaker Shire PLC on Friday said its drug Lanadelumab was found to significantly reduce hereditary angioedema attacks in a recent study.
Hereditary angioedema is a rare genetic disorder that causes swelling in various parts of the body. This swelling can be debilitating and painful, as well as potentially life-threatening when swelling occurs in such a way as to obstruct the airways.
Shire, which is being acquired by Takeda Pharmaceutical Co Ltd, said data from its Phase III Help study showed that hereditary angioedema patients taking Lanadelumab suffered fewer attacks versus placebo.
The study involved administering 300 milligrams of Lanadelumab every two weeks for a 26-week period.
In addition to experiencing a reduced number of attacks, patients taking Lanadelumab were also less likely to experience moderate or severe attacks.
Those taking Lanadelumab were also less likely to use rescue medication and were more likely to be hereditary angioedema attack-free during the treatment period.
Interim results from the Help study open-label extension also found that the drug was "generally well-tolerated", consistent with its previous safety profile.
When interim analysis was conducted, patients had been exposed to Lanadelumab for a mean of more than 8 months and continued to experience a reduction in attacks.
"Additional analysis of the Help study continues to support the use of Lanadelumab as a preventive subcutaneous treatment option for [hereditary angioedema] in appropriate patients 12 years of age and older," said Shire executive vice president, and head of research & development, Andreas Busch.
"The data we have seen from the Help open-label extension are very promising and we look forward to receiving the final results," Busch added.
Shares in Shire were down 0.2% at 4,610.00p.
Separately, Takeda said it has launched the offering of its unsecured USD-denominated senior notes due 202, 2021, 2023 and 2018 and announced the pricing of its unsecured EUR-denominated senior notes on Friday.
The EUR notes due 2020, 2022, 2026, and 2030 will raise an aggregate of EUR7.50 billion for Takeda.
Proceeds from both these note issues will be used to finance Takeda's GBP46.0 billion Shire acquisition, and to reduce commitments under is 364-day bridge credit agreement in connection with the acquisition.
By Anna Farley; annafarley@alliancenews.com
Copyright 2018 Alliance News Limited. All Rights Reserved.
http://www.morningstar.co.uk/uk/news/AN_1542360265876422700/top-news-lanadelumab-cuts-hereditary-angioedema-events-in-shire-study.aspxBagikan Berita Ini
0 Response to "TOP NEWS: Lanadelumab Cuts Hereditary Angioedema Events In Shire Study"
Post a Comment